Boston Scientific Corporation $BSX Stock: Quadrant Capital Group LLC Cuts Stake

Quadrant Capital Group LLC cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 70.8% in the third quarter, HoldingsChannel reports. The fund owned 19,732 shares of the medical equipment provider’s stock after selling 47,951 shares during the period. Quadrant Capital Group LLC’s holdings in Boston Scientific were worth $855,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its position in shares of Boston Scientific by 44.9% in the third quarter. Physician Wealth Advisors Inc. now owns 1,090 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 338 shares during the period. Pinnacle Associates Ltd. increased its stake in shares of Boston Scientific by 26.7% in the third quarter. Pinnacle Associates Ltd. now owns 21,182 shares of the medical equipment provider’s stock worth $925,000 after purchasing an additional 4,469 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Boston Scientific by 4.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 217,879 shares of the medical equipment provider’s stock valued at $9,510,000 after purchasing an additional 9,227 shares during the period. Integrated Advisors Network LLC raised its position in shares of Boston Scientific by 256.2% during the 3rd quarter. Integrated Advisors Network LLC now owns 24,243 shares of the medical equipment provider’s stock valued at $1,058,000 after purchasing an additional 17,437 shares during the period. Finally, Louisbourg Investments Inc. raised its position in shares of Boston Scientific by 6.2% during the 3rd quarter. Louisbourg Investments Inc. now owns 194,330 shares of the medical equipment provider’s stock valued at $8,483,000 after purchasing an additional 11,377 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. Rothschild & Co Redburn lowered their target price on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 price target (down from $75.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Oppenheimer decreased their price target on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a report on Monday, September 21st. Evercore decreased their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a report on Wednesday, October 7th. Finally, Raymond James Financial restated an “outperform” rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Trading Down 0.7%

Boston Scientific stock opened at $45.67 on Friday. Boston Scientific Corporation has a 1 year low of $41.38 and a 1 year high of $105.65. The firm’s 50 day moving average price is $45.46 and its 200-day moving average price is $49.16. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a market cap of $66.19 billion, a P/E ratio of 18.49, a PEG ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward Ludwig acquired 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.